The Sigma Healthcare Ltd (ASX: SIG) share price is in focus today after the company reported a 15.5% lift in revenue to $10.8 billion and a 20.6% surge in normalised EBIT to $1.09 billion for FY26, its first full-year result since merging with Chemist Warehouse Group.

What did Sigma Healthcare report?

• Revenue: $10.8 billion, up 15.5% year on year
• Normalised EBIT: $1,090.0 million, up 20.6%, with margin rising to 10.1%
• Normalised NPAT: $732.3 million, up 22.3%
• Net debt reduced to $663 million (Debt to Normalised EBITDA: 0.57x)
• Integration synergies delivered: $32.6 million, aiming for $100 million p.a. by FY29
• Fully franked final dividend: 2.0 cents per share (full year: 4.0 cents per share)

What else do investors need to know?

Sigma’s Australian business remains its “engine room”, contributing $10.4 billion in revenue and $1,034.2 million in normalised EBIT. The international arm is gathering momentum, delivering 33% revenue growth and doubling EBIT, with Ireland now profitable and a push into the UK market underway.

Sigma added 24 Chemist Warehouse branded stores in Australia, reaching 561 stores, while opening 20 new international outlets. The company continued to expand its own and exclusive-label products, with annual sales near $1 billion and the Wagner Pharmaceuticals generic business growing over 30%.

What did Sigma Healthcare management say?

Sigma’s CEO, Vikesh Ramsunder, said:

FY26 demonstrates that Sigma is not simply larger after the merger, it is structurally stronger. Our highly scalable business model is underpinned by defensive industry characteristics. With the Australian infrastructure already in place and a clearly defined runway to keep growing, we are confident the model will keep compounding value.

What’s next for Sigma Healthcare?

Sigma’s FY27 agenda centres on growing its network, driving operating leverage, and boosting product differentiation. The company aims to open 13 new Chemist Warehouse stores in Australia and 19 internationally in the first half, including its entry into the UK. Refreshed growth in the Amcal and Discount Drug Stores brands is also expected, with 42 new Australian stores on the way.

With a capital-light model and a solid balance sheet, Sigma is targeting sustained growth and long-term shareholder value, with over half of planned synergy savings still to be realised.

Sigma Healthcare share price snapshot

The Sigma Healthcare share price has underperformed the S&P/ASX 200 index (ASX: XJO) on a 12-month basis with a decline of almost 7%.

View Original Announcement

The post Sigma Healthcare FY26 earnings: Record profit as Chemist Warehouse merger delivers growth appeared first on The Motley Fool Australia.

More reading

• My top 5 ASX 200 shares to buy and hold
• Why I’d buy Coles, Telstra and this ASX 200 blue chip share for retirement
• ASX 200 technology and healthcare shares continued their comeback last week
• 3 ASX 200 blue-chip shares I’d buy now

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Bapcor Ltd (ASX: BAP) share price is in focus today after the company reported a statutory net loss of $431.6 million in FY26, driven mainly by non-cash impairment charges, while underlying EBITDA exceeded the top end of May’s guidance.

What did Bapcor report?

• Underlying revenue of $1,924.1 million, down 1.8% from FY25
• Statutory net loss after tax of $431.6 million, impacted by $442.4 million in post-tax significant items
• Underlying EBITDA of $152.5 million, exceeding guidance
• Underlying NPAT of $10.8 million, down 85.0% year-on-year
• Net bank debt reduced to $135.0 million from $364.8 million in FY25
• No final dividend declared to prioritise cash during the turnaround

What else do investors need to know?

Bapcor’s FY26 was a year of transition and turnaround, marked by the appointment of a new CEO, Chair, and strengthened leadership team. The second half saw improved operating momentum, with working capital initiatives delivering $68.5 million in cash flow and cash conversion rising sharply to 109.4%.

The company completed a $200 million equity raising in February 2026, helping to materially strengthen its balance sheet and reduce net debt. Bapcor also implemented cost and efficiency improvements, focusing on enhancing price competitiveness, stock availability, and customer engagement across its business units.

What did Bapcor management say?

Chief Executive Officer and Managing Director, Chris Wilesmith, said:

Since joining Bapcor in January, our priority has been restoring the fundamentals of the business. The actions implemented during the second half improved performance across the Group. Sales momentum improved across the Group through the final 5 months of the year, Networks returned to growth, Retail delivering positive like-for-like sales growth, and our working capital initiatives are delivering real value.

What’s next for Bapcor?

Looking ahead, Bapcor plans to build on its recent improvements with an ongoing turnaround program and a broader strategic review to clarify long-term priorities. The company is also considering divesting smaller, non-core assets to sharpen its focus on critical, high-return businesses.

In FY27, management expects modest revenue growth with trading momentum tipped to improve further. Early trading for the first six weeks shows sales slightly ahead of last year, although macroeconomic and geopolitical uncertainties persist. Profits are likely to be more heavily weighted to the second half of the year.

Bapcor share price snapshot

Over the past 12 months, the Bapcor share price has significantly underperformed the S&P/ASX 200 Index (ASX: XJO) with an 85% decline as operational challenges weighed on investor sentiment.

View Original Announcement

The post Bapcor Ltd FY26 earnings: turnaround gains, big impairment loss appeared first on The Motley Fool Australia.

More reading

• Bapcor reaffirms FY26 EBITDA guidance
• Down 84%, why Bapcor shares may have further to fall
• 3 ASX All Ords shares to sell this week: Experts

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Perpetual Ltd (ASX: PPT) share price is in focus as the company reports a 6% rise in underlying profit after tax (UPAT) to $217 million and declares a final unfranked dividend of 63 cents per share.

What did Perpetual report?

• FY26 operating revenue of $1,374.2 million (flat year-on-year)
• UPAT of $217.0 million, up 6% from FY25
• Statutory net profit after tax (NPAT) of $88.9 million, recovering from a $58.2 million loss in FY25
• Corporate Trust profit before tax up 9% to $98.8 million
• Final dividend of 63 cents per share (unfranked); total FY26 dividends $1.22 per share (65% payout ratio)
• Annualised cost savings of $72.6 million delivered under the Simplification Program

What else do investors need to know?

Perpetual signed a binding agreement in March 2026 to sell its Wealth Management division to Bain Capital. This move is a key part of the company’s simplification strategy, with the transaction expected to complete in the final quarter of 2026, subject to regulatory approvals.

The group continued to reduce debt, lowering gross debt by 15% over the past year to $629.3 million. Proceeds from the Wealth Management sale are expected to further strengthen the balance sheet, supporting future investment in Asset Management and Corporate Trust.

Significant items after tax were $128.1 million, mainly related to transaction and separation costs from the Wealth Management sale, impairment charges, and costs tied to the ongoing Simplification Program.

What did Perpetual management say?

Perpetual CEO and Managing Director Bernard Reilly said:

FY26 was a positive year despite mixed market conditions. We delivered strong earnings growth and improved profitability against a backdrop of geopolitical uncertainty and corporate change, highlighting the benefits of our diversified business model.

What’s next for Perpetual?

Perpetual’s top priority is completing the sale of Wealth Management, marking a further step in its transition to a simpler organisation. After the sale, Perpetual plans to focus on its Asset Management and Corporate Trust businesses—aiming for consistent earnings, a stronger balance sheet, and greater financial flexibility.

Perpetual is also pursuing ongoing cost efficiencies and digital transformation in Corporate Trust and is targeting fresh product innovation and global growth in Asset Management, including a turnaround plan for its J O Hambro boutique.

Perpetual share price snapshot

The Perpetual share price has underperformed the S&P/ASX 200 index (ASX: XJO) over the past 12 months with a decline of almost 12%.

View Original Announcement

The post Perpetual posts higher FY26 profit and readies for business sale appeared first on The Motley Fool Australia.

More reading

• Perpetual reveals $63.5m impairment after major fund redemption
• These were the best-performing ASX 200 shares in July
• Perpetual lifts AUM, advances Wealth sale in Q4 FY26 update

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.